(Q24234403)

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Low molecular weight heparin as adjuvant therapy in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Thrombotic vascular risk factors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Novel drug development opportunities for heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Cyclosporine A for induction of remission in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

Response to heparin in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021

Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021

Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021

Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021

Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021

Mucosal capillary thrombi in rectal biopsies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021

Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006774.PUB3

7 January 2021